<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17	PATIENT COUNSELING INFORMATION<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.1 Patient Counseling<BR>                     <BR>                        Patients should be advised of the potential benefits and risks of ZELBORAF. Physicians should instruct their patients to read the Medication Guide before starting ZELBORAF therapy.<BR>                        <BR>                           <BR>                              BRAFV600E Testing<BR>                              <BR>Inform patients that an assessment of BRAFV600E mutation with the cobas®<BR>                               4800 BRAF V600 Mutation Test (or other FDA approved test) is required for selection of patients appropriate for ZELBORAF therapy. These patients are the only patients studied and for whom benefit has been shown [see Warnings and Precautions (5.10) and Clinical Studies (14)].<BR>                           <BR>                              Cutaneous Squamous Cell Carcinoma (cuSCC)<BR>                              <BR>Inform patients that cases of cuSCC have been reported in patients treated with ZELBORAF. Inform patients that their doctor will check their skin regularly during treatment and up to 6 months after treatment. Instruct the patient of the importance of contacting their doctor immediately of any changes in their skin [see Warnings and Precautions (5.1)].<BR>                           <BR>                              Photosensitivity<BR>                              <BR>Advise patients to avoid sun exposure while taking ZELBORAF. While taking the drug, patients should be advised to wear protective clothing and use a broad spectrum UVA/UVB sunscreen and lip balm (SPF ≥ 30) when outdoors to help protect against sunburn [see Warnings and Precautions (5.6)].<BR>                           <BR>                              Other Common Events<BR>                              <BR>Other commonly reported adverse events included arthralgia, rash, alopecia, fatigue, photosensitivity reactions, nausea, pruritus and skin papilloma [see Adverse Reactions (6.1)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>